title: Justifying research risks in a clinical trial for treatment of multidrug-resistant tuberculosis.
authors.affiliation: Division of Tuberculosis Elimination, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
authors.forename: Charles M
authors.initials: CM
authors.lastname: Heilig
authors.forename: David
authors.initials: D
authors.lastname: Chia
authors.forename: Wafaa M
authors.initials: WM
authors.lastname: El-Sadr
authors.forename: Yael
authors.initials: Y
authors.lastname: Hirsch-Moverman
authors.forename: William R Mac
authors.initials: WR
authors.lastname: Kenzie
authors.forename: Jussi
authors.initials: J
authors.lastname: Saukkonen
authors.forename: Margarita E
authors.initials: ME
authors.lastname: Villarino
authors.forename: Nesri
authors.initials: N
authors.lastname: Padayatchi
mesh_terms: D000081:Acetamides / Q000009:adverse effects / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D000069349:Linezolid; D023303:Oxazolidinones / Q000009:adverse effects / Q000627:therapeutic use; D010919:Placebos; D016032:Randomized Controlled Trials as Topic / Q000941:ethics*; D018570:Risk Assessment; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D000081:Acetamides; D000995:Antitubercular Agents; D023303:Oxazolidinones; D010919:Placebos; D000069349:Linezolid